SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.8B
Q2 2021
Positions
95
Filings on Record
27
2019–present window
Filed
Aug 16, 2021
original filing

Summary

Boxer Capital, LLC reported $2.8B in U.S.-listed holdings across 95 positions for Q2 2021.

Its largest position, MRTXEUR, represents 11.4% of the portfolio.

Compared with Q1 2021, the fund opened 13 new positions and exited 3.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Top-10 Concentration
+46.0%
share of reported value
Largest Position
+11.4%
Mirati Therapeutics
New / Exited
13 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 71.2%Other: 15.4%ADR: 13.3%Equity WRT: 0.0%
  • Common Stock · 71.2% · $2.0B
  • Other · 15.4% · $438M
  • ADR · 13.3% · $378M
  • Equity WRT · 0.0% · $693,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BMEABiomea Fusion Inc.NEW+2.09M2.09M+$33M$33M
DAWNGBXDay One Biopharmaceuticals Inc.NEW+1.19M1.19M+$27M$27M
GH Research PLCNEW+1.01M1.01M+$22M$22M
260Centessa Pharmaceuticals PLCNEW+904.2K904.2K+$20M$20M
Rain Therapeutics Inc.NEW+1.18M1.18M+$18M$18M
Elevation Oncology Inc.NEW+1.34M1.34M+$18M$18M
XENEXenon Pharmaceuticals Inc.NEW+857.0K857.0K+$16M$16M
F-Star Therapeutics Inc.NEW+1.75M1.75M+$15M$15M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMirati Therapeutics Inc.history →COM11.40%$323M2.00M
2ONCBeiGene Ltdhistory →SPONSORED ADR9.25%$262M764.2K
3SWTXUSDSpringworks Therapeutics Inc.history →COM6.04%$171M2.08M
42662247DiTeos Therapeutics Inc.history →COM3.93%$111M4.35M
5RVMDRevolution Medicines Inc.history →COM3.90%$111M3.48M
6PMVPPMV Pharmaceuticals Inc.history →COM2.73%$77M2.27M
7RCKTRocket Pharmaceuticals Inc.history →COM2.29%$65M1.47M
8SGENUSDSeagen Inc.history →COM2.23%$63M400.0K
9SG7Sage Therapeutics Inc.history →COM2.19%$62M1.09M
10RCUSArcus Biosciences Inc.history →COM2.02%$57M2.08M
11SPRYSilverback Therapeutics Inc.history →COM1.83%$52M1.68M
12ARGXArgenX SEhistory →SPONSORED ADR1.82%$51M170.9K
13RLAYRelay Therapeutics Inc.history →COM1.67%$47M1.29M
14IDYAIdeaya Biosciences Inc.history →COM1.63%$46M2.20M
15Marinus Pharmaceuticals Inc.COM NEW1.52%$43M2.40M
16CYTKCytokinetics Inc.history →COM NEW1.47%$42M2.10M
17DBV Technologies SASPONSORED ADR1.45%$41M7.53M
18Connect Biopharma Holdings Ltd.ADS1.43%$41M2.08M
19NUVBNuvation Bio Inc.history →COM CL A1.43%$40M4.34M
20Merus NVCOM1.41%$40M1.90M
21SNDXSyndax Pharmaceuticals Inc.history →COM1.39%$39M2.29M
22ANABAnaptys Bio Inc.history →COM1.19%$34M1.30M
23BMEABiomea Fusion Inc.history →COM1.15%$33M2.09M
24NRIXNurix Therapeutics Inc.history →COM1.15%$32M1.22M
25Aligos Therapeutics Inc.COM1.10%$31M1.53M
26BCABGBPBioAtla Inc.history →COM1.03%$29M686.3K
27RNAGBPAvidity Biosciences Inc.history →COM NEW0.98%$28M1.12M
28CGEMCullinan Oncology Inc.history →COM0.98%$28M1.07M
29DAWNGBXDay One Biopharmaceuticals Inc.history →COM0.96%$27M1.19M
30Amarin Corp PLCSPONS ADR NEW0.93%$26M6.00M
31Therapeutics Acquisition CorpCOM CL A0.91%$26M2.50M
32Passage Bio Inc.COM0.90%$26M1.93M
33KNTEUSDKinnate Biopharma Inc.history →COM0.88%$25M1.07M
34BDTXBlack Diamond Therapeutics Inc.history →COM0.87%$25M2.01M
35KDMNKadmon Holdings Inc.history →COM0.85%$24M6.21M
36AM6Amicus Therapeutics Inc.history →COM0.79%$22M2.33M
37GH Research PLCORDINARY SHARES0.78%$22M1.01M
38AGENEURAgenus Inc.history →COM NEW0.77%$22M4.00M
39KURAKura Oncology Inc.history →COM0.77%$22M1.05M
40BMRNBiomarin Pharmaceutical Inc.history →COM0.74%$21M250.0K
41GOSSGossamer Bio Inc.history →COM0.73%$21M2.56M
42AKROAkero Therapeutics Inc.history →COM0.73%$21M831.5K
43260Centessa Pharmaceuticals PLChistory →SPONSORED ADS0.71%$20M904.2K
44MREOMereo Biopharma Group PLChistory →ADS0.70%$20M6.23M
45EPIEUREssa Pharma Inc.history →COM0.69%$20M687.0K
46Odonate Therapeutics Inc.COM0.69%$20M5.61M
4732WCodiak Biosciences Inc.history →COM0.67%$19M1.03M
48Atreca Inc.CL A COM0.66%$19M2.20M
49Cerevel Therapeutics Holding Inc.COM CL A0.65%$18M714.5K
50Rain Therapeutics Inc.COM0.64%$18M1.18M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.